Literature DB >> 20346413

Naturally occurring human plasminogen, like genetically related apolipoprotein(a), contains oxidized phosphatidylcholine adducts.

Celina Edelstein1, Ditta Pfaffinger, Ming Yang, John S Hill, Angelo M Scanu.   

Abstract

Human apolipoprotein(a) (apo(a)), synthesized in the liver, contains oxidized phosphatidylcholine (oxPtdPC) adducts probably generated at the hepatic site. Since plasminogen (Plg), also synthesized in the liver, is genetically related and structurally homologous to apo(a), we wanted to determine whether it contains oxPtdPCs and their location. We used Plg isolated from fresh or frozen normal human plasma and several commercial preparations. Some were freed of non-covalently bound lipids by organic solvent extraction. By immunoblot analyses, all products reacted against T15, a natural IgM monoclonal antibody specific for phosphorylcholine -containing oxidized phospholipids (ox-PLs). This immunoreactivity was retained in urokinase type plasminogen activator -generated plasmin and was abrogated in Plg previously digested with lipoprotein-associated phospholipase A(2) (Lp-PLA(2)), a reaction that generated predominantly C16:0 lysophosphatidylcholine species as determined by mass spectrometry. Lyso derivatives were also generated upon the cleavage by Lp-PLA2 of a model ox-PL chemically linked to a lysine-containing pentapeptide. From inorganic phosphorous analyses, we found 2 mol of oxPtdPC/mole of Plg distributed between the kringles 1-4 and mini-Plg domain. OxPtdPCs were also present in the Plg isolated from the serum-free medium of cultured human HepG2 cells. In conclusion, our results provide strong evidence that naturally occurring Plg contains oxPtdPC probably linked by a Schiff base and also suggest that the linkage occurs at the hepatic site. Given the emerging evidence for the cardiovascular pathogenicity of oxPtdPCs, we speculate that they may impart athero-thrombogenic properties to Plg under inflammatory conditions. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20346413      PMCID: PMC2878871          DOI: 10.1016/j.bbalip.2010.03.009

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  29 in total

1.  Plasminogen: purification from human plasma by affinity chromatography.

Authors:  D G Deutsch; E T Mertz
Journal:  Science       Date:  1970-12-04       Impact factor: 47.728

2.  Correlation of antiphospholipid antibody recognition with the structure of synthetic oxidized phospholipids. Importance of Schiff base formation and aldol condensation.

Authors:  Peter Friedman; Sohvi Horkko; Daniel Steinberg; Joseph L Witztum; Edward A Dennis
Journal:  J Biol Chem       Date:  2001-12-14       Impact factor: 5.157

Review 3.  Apolipoprotein(a): structure and biology.

Authors:  A M Scanu; K Nakajima; C Edelstein
Journal:  Front Biosci       Date:  2001-03-01

4.  Demonstration that the enzyme that converts precursor of apolipoprotein A-I to apolipoprotein A-I is secreted by the hepatocarcinoma cell line Hep G2.

Authors:  C Edelstein; M Kaiser; G Piras; A M Scanu
Journal:  Arch Biochem Biophys       Date:  1988-11-15       Impact factor: 4.013

5.  Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity.

Authors:  P X Shaw; S Hörkkö; M K Chang; L K Curtiss; W Palinski; G J Silverman; J L Witztum
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

6.  Lysine-phosphatidylcholine adducts in kringle V impart unique immunological and potential pro-inflammatory properties to human apolipoprotein(a).

Authors:  Celina Edelstein; Ditta Pfaffinger; Janet Hinman; Elizabeth Miller; Gregory Lipkind; Sotirios Tsimikas; Claes Bergmark; Godfrey S Getz; Joseph L Witztum; Angelo M Scanu
Journal:  J Biol Chem       Date:  2003-10-13       Impact factor: 5.157

7.  The role of oxidized phospholipids in atherosclerosis.

Authors:  Judith A Berliner; Norbert Leitinger; Sotirios Tsimikas
Journal:  J Lipid Res       Date:  2008-12-04       Impact factor: 5.922

Review 8.  The functions of plasminogen in cardiovascular disease.

Authors:  Edward F Plow; Jane Hoover-Plow
Journal:  Trends Cardiovasc Med       Date:  2004-07       Impact factor: 6.677

Review 9.  Antiangiogenic cancer therapy.

Authors:  Yihai Cao
Journal:  Semin Cancer Biol       Date:  2004-04       Impact factor: 15.707

Review 10.  Angiostatin.

Authors:  Yihai Cao; Lexun Xue
Journal:  Semin Thromb Hemost       Date:  2004-02       Impact factor: 4.180

View more
  11 in total

Review 1.  Oxidation-specific epitopes as targets for biotheranostic applications in humans: biomarkers, molecular imaging and therapeutics.

Authors:  Yury I Miller; Sotirios Tsimikas
Journal:  Curr Opin Lipidol       Date:  2013-10       Impact factor: 4.776

Review 2.  Oxidative lipidomics coming of age: advances in analysis of oxidized phospholipids in physiology and pathology.

Authors:  Corinne M Spickett; Andrew R Pitt
Journal:  Antioxid Redox Signal       Date:  2015-03-26       Impact factor: 8.401

Review 3.  Bioactive oxidatively truncated phospholipids in inflammation and apoptosis: formation, targets, and inactivation.

Authors:  Thomas M McIntyre
Journal:  Biochim Biophys Acta       Date:  2012-03-16

4.  Circulating levels of plasminogen and oxidized phospholipids bound to plasminogen distinguish between atherothrombotic and non-atherothrombotic myocardial infarction.

Authors:  Andrew P DeFilippis; Ilya Chernyavskiy; Alok R Amraotkar; Patrick J Trainor; Shalin Kothari; Imtiaz Ismail; Charles W Hargis; Frederick K Korley; Gregor Leibundgut; Sotirios Tsimikas; Shesh N Rai; Aruni Bhatnagar
Journal:  J Thromb Thrombolysis       Date:  2016-07       Impact factor: 2.300

Review 5.  Lipoprotein-associated phospholipase A2: The story continues.

Authors:  Fubao Huang; Kai Wang; Jianhua Shen
Journal:  Med Res Rev       Date:  2019-05-29       Impact factor: 12.944

6.  Oxidized phospholipids are present on plasminogen, affect fibrinolysis, and increase following acute myocardial infarction.

Authors:  Gregor Leibundgut; Kiyohito Arai; Alexina Orsoni; Huiyong Yin; Corey Scipione; Elizabeth R Miller; Marlys L Koschinsky; M John Chapman; Joseph L Witztum; Sotirios Tsimikas
Journal:  J Am Coll Cardiol       Date:  2012-04-17       Impact factor: 24.094

Review 7.  Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis.

Authors:  Calvin Yeang; Michael J Wilkinson; Sotirios Tsimikas
Journal:  Curr Opin Cardiol       Date:  2016-07       Impact factor: 2.161

Review 8.  Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?

Authors:  Michael B Boffa; Marlys L Koschinsky
Journal:  J Lipid Res       Date:  2015-12-08       Impact factor: 5.922

9.  Mouse plasminogen has oxidized phosphatidylcholine adducts that are not metabolized by lipoprotein-associated phospholipase A₂under basal conditions.

Authors:  Celina Edelstein; Ditta Pfaffinger; Ethan C Reichert; Diana M Stafforini; Angelo M Scanu
Journal:  Int J Mol Sci       Date:  2010-12-22       Impact factor: 5.923

10.  Atherothrombotic factors and atherosclerotic cardiovascular events: the multi-ethnic study of atherosclerosis.

Authors:  Andrew P DeFilippis; Patrick J Trainor; George Thanassoulis; Lyndia C Brumback; Wendy S Post; Michael Y Tsai; Sotirios Tsimikas
Journal:  Eur Heart J       Date:  2022-03-07       Impact factor: 35.855

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.